Published in Pharmacol Rev on June 01, 1997
Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43
Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol (2000) 2.64
Mast cells and inflammation. Biochim Biophys Acta (2010) 1.91
Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol (2005) 1.80
Peripheral markers of brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci (2003) 1.56
Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis. Brain (2015) 1.40
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci U S A (1999) 1.38
In vitro blood-brain barrier models: current and perspective technologies. J Pharm Sci (2011) 1.36
A mouse model of blast-induced mild traumatic brain injury. Exp Neurol (2011) 1.20
Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol (2009) 1.11
Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc Natl Acad Sci U S A (2007) 1.05
Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One (2010) 1.04
Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. PLoS One (2013) 1.00
Nanoparticles for brain drug delivery. ISRN Biochem (2013) 0.99
Molecular and cellular immune responses to ischemic brain injury. Transl Stroke Res (2014) 0.99
Cardiac arrest-induced regional blood-brain barrier breakdown, edema formation and brain pathology: a light and electron microscopic study on a new model for neurodegeneration and neuroprotection in porcine brain. J Neural Transm (Vienna) (2010) 0.98
Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci (2014) 0.97
Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab (2006) 0.97
APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J Neurochem (2015) 0.96
Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest. ACS Nano (2014) 0.96
Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol (2003) 0.95
Genomics of the fetal hypothalamic cellular response to transient hypoxia: endocrine, immune, and metabolic responses. Physiol Genomics (2013) 0.93
Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin. Antimicrob Agents Chemother (2003) 0.92
Estimation of cerebrospinal fluid cortisol level in tuberculous meningitis. J Neurosci Rural Pract (2016) 0.91
HUCBCs increase angiopoietin 1 and induce neurorestorative effects after stroke in T1DM rats. CNS Neurosci Ther (2014) 0.91
Qualitative prediction of blood-brain barrier permeability on a large and refined dataset. J Comput Aided Mol Des (2011) 0.89
The Role of Glycogen Synthase Kinase 3 Beta in Neuroinflammation and Pain. J Pharm Pharmacol (Los Angel) (2013) 0.88
Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain. Acta Neuropathol (2012) 0.88
Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier. Pharm Res (2014) 0.87
Endothelin-1 reduces p-glycoprotein transport activity in an in vitro model of human adult blood-brain barrier. Cell Mol Neurobiol (2008) 0.87
Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun (2015) 0.85
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev Clin Pharmacol (2013) 0.84
Ischemic preconditioning mediates cyclooxygenase-2 expression via nuclear factor-kappa B activation in mixed cortical neuronal cultures. Transl Stroke Res (2010) 0.84
Effects of peripheral inflammation on the blood-spinal cord barrier. Mol Pain (2012) 0.84
Oxidative Stress and the Use of Antioxidants in Stroke. Antioxidants (Basel) (2014) 0.84
Magnetic resonance imaging of monocytes labeled with ultrasmall superparamagnetic particles of iron oxide using magnetoelectroporation in an animal model of multiple sclerosis. Mol Imaging (2010) 0.83
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases. Nanomedicine (2015) 0.82
Efficacy of N-acetyl cysteine in traumatic brain injury. PLoS One (2014) 0.82
Possible involvement of TLRs and hemichannels in stress-induced CNS dysfunction via mastocytes, and glia activation. Mediators Inflamm (2013) 0.81
Prediction of blood-brain partitioning using Monte Carlo simulations of molecules in water. J Comput Aided Mol Des (2001) 0.80
Synthesis and in Vitro Studies of a Series of Carborane-Containing Boron Dipyrromethenes (BODIPYs). J Med Chem (2016) 0.79
Does Systemic Inflammation Play a Role in Pediatric Psychosis? Clin Schizophr Relat Psychoses (2013) 0.79
Gene expression profiles and protein-protein interaction network analysis in AIDS patients with HIV-associated encephalitis and dementia. HIV AIDS (Auckl) (2015) 0.78
Distribution and clearance of retained gadolinium in the brain: differences between linear and macrocyclic gadolinium based contrast agents in a mouse model. Br J Radiol (2016) 0.78
A Systematic, Integrated Study on the Neuroprotective Effects of Hydroxysafflor Yellow A Revealed by (1)H NMR-Based Metabonomics and the NF-κB Pathway. Evid Based Complement Alternat Med (2013) 0.78
Heparin Attenuates the Expression of TNFalpha-induced Cerebral Endothelial Cell Adhesion Molecule. Korean J Physiol Pharmacol (2008) 0.78
Analysis of neurogenesis during experimental autoimmune encephalomyelitis reveals pitfalls of bioluminescence imaging. PLoS One (2015) 0.78
Nanoscale effects in dendrimer-mediated targeting of neuroinflammation. Biomaterials (2016) 0.78
Gold nanoparticles as multimodality imaging agents for brain gliomas. J Nanobiotechnology (2015) 0.77
Inhibition of Myeloperoxidase at the Peak of Experimental Autoimmune Encephalomyelitis Restores Blood-Brain-Barrier Integrity and Ameliorates Disease Severity. J Neurochem (2015) 0.77
Cerebrovascular toxicity of PCB153 is enhanced by binding to silica nanoparticles. J Neuroimmune Pharmacol (2012) 0.77
Dorsal raphe neuroinflammation promotes dramatic behavioral stress dysregulation. J Neurosci (2014) 0.77
Brain trauma enhances transient cytomegalovirus invasion of the brain only in mice that are immunodeficient. J Virol (2008) 0.76
Factor V activator from Daboia russelli russelli venom destabilizes β-amyloid aggregate, the hallmark of Alzheimer disease. J Biol Chem (2013) 0.76
Blood-CSF barrier and compartmentalization of CNS cellular immune response in HIV infection. J Neuroimmunol (2016) 0.76
Evaluation of the role of erythropoietin and methotrexate in multiple sclerosis. Indian J Pharmacol (2011) 0.75
Alzheimer's Disease: Assessing the Role of Spirochetes, Biofilms, the Immune System, and Amyloid-β with Regard to Potential Treatment and Prevention. J Alzheimers Dis (2016) 0.75
Transient life-threatening cerebral edema in a patient with systemic lupus erythematosus. J Clin Rheumatol (2009) 0.75
Inhibition of T-cell activation attenuates hypertension, TNFα, IL-17, and blood-brain barrier permeability in pregnant rats with angiogenic imbalance. Am J Reprod Immunol (2016) 0.75
Histamine Induces Alzheimer's Disease-Like Blood Brain Barrier Breach and Local Cellular Responses in Mouse Brain Organotypic Cultures. Biomed Res Int (2015) 0.75
In vivo imaging with bioluminescent enterovirus 71 allows for real-time visualization of tissue tropism and viral spread. J Virol (2016) 0.75
Kinin Peptides Enhance Inflammatory and Oxidative Responses Promoting Apoptosis in a Parkinson's Disease Cellular Model. Mediators Inflamm (2016) 0.75
An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs. PLoS Negl Trop Dis (2016) 0.75
Improved Automated Radiosynthesis of [(11)C]PBR28. Sci Pharm (2015) 0.75
Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism (2016) 0.75
Serum Neuroinflammatory Disease-Induced Central Nervous System Proteins Predict Clinical Onset of Experimental Autoimmune Encephalomyelitis. Front Immunol (2017) 0.75
The Connected Steady State Model and the Interdependence of the CSF Proteome and CSF Flow Characteristics. Front Neurosci (2017) 0.75
Therapeutic drug monitoring in saliva. Clin Pharmacokinet (1978) 2.66
The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol (1996) 2.34
Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology (1979) 2.31
Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol (1983) 1.78
Pharmacokinetics and metabolism of various benzodiazepines used as hypnotics. Br J Clin Pharmacol (1979) 1.75
Vascular adhesion molecule-1 and intercellular adhesion molecule-1 expression on rat liver cells after lipopolysaccharide administration in vivo. Hepatology (1995) 1.69
The impact and recovery of asteroid 2008 TC(3). Nature (2009) 1.60
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol (1984) 1.60
Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem (2001) 1.59
Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet (1982) 1.57
Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers. Br J Clin Pharmacol (1979) 1.55
Structural characterisation of the exopolysaccharide produced by Lactobacillus delbrückii subspecies bulgaricus rr grown in skimmed milk. Carbohydr Res (1993) 1.49
Pharmacokinetics of rectal drug administration, Part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet (1991) 1.46
Differential effects of enzyme induction on antipyrine metabolite formation. Br J Clin Pharmacol (1982) 1.43
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther (1992) 1.41
Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation (2006) 1.41
Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther (1987) 1.41
Automated high-performance liquid chromatographic determination of antipyrine and its main metabolites in plasma, saliva and urine, including 4,4'-dihydroxyantipyrine. J Chromatogr (1983) 1.39
Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev (2000) 1.37
Studies on the different metabolic pathways of antipyrine in rats: influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica (1979) 1.37
Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun (2009) 1.36
Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur J Clin Pharmacol (1975) 1.35
Multidrug resistance P-glycoprotein hampers the access of cortisol but not of corticosterone to mouse and human brain. Endocrinology (2001) 1.32
Clinical pharmacokinetics of hypnotics. Clin Pharmacokinet (1977) 1.32
Interindividual variations in drug disposition. Clinical implications and methods of investigation. Clin Pharmacokinet (1983) 1.32
Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther (1984) 1.32
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J (2001) 1.31
High prevalence of the neurotrope Exophiala dermatitidis and related oligotrophic black yeasts in sauna facilities. Mycoses (2002) 1.31
Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. Endocrinology (1998) 1.30
Patient satisfaction with occupational health physicians, development of a questionnaire. Occup Environ Med (2005) 1.26
Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes. Eur J Pharm Sci (2001) 1.26
The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol (1999) 1.25
A novel link between Campylobacter jejuni bacteriophage defence, virulence and Guillain-Barré syndrome. Eur J Clin Microbiol Infect Dis (2012) 1.24
Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem (1990) 1.24
Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol (1997) 1.22
Assay of triazolam in plasma by capillary gas chromatography. J Chromatogr (1981) 1.22
Hormonal control of glycogenolysis in parenchymal liver cells by Kupffer and endothelial liver cells. J Biol Chem (1988) 1.21
Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells. Mol Pharmacol (1989) 1.21
Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev Pharmacol Toxicol (2008) 1.20
FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med (2000) 1.19
Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. J Clin Invest (1997) 1.18
Structure of the exopolysaccharide produced by Lactococcus lactis subspecies cremoris H414 grown in a defined medium or skimmed milk. Carbohydr Res (1992) 1.17
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev (2001) 1.17
Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther (1991) 1.16
ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. Curr Drug Targets (2011) 1.15
Role of macrophage-derived lipoprotein lipase in lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol (2000) 1.14
Pharmacokinetic interactions with rifampicin. Clin Pharmacokinet (1977) 1.14
A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. Clin Pharmacol Ther (1991) 1.14
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev (1997) 1.13
Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol (1982) 1.13
Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J Control Release (1998) 1.12
Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol (1988) 1.11
Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet (1982) 1.11
Influence of sex and oral contraceptive steroids on antipyrine metabolite formation. Clin Pharmacol Ther (1982) 1.10
Pharmacokinetics of benzodiazepines. Short-acting versus long-acting. Arzneimittelforschung (1980) 1.10
Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci (2000) 1.10
Fate and effects of 4-chlorophenol and 2,4-dichlorophenol in marine plankton communities in experimental enclosures. Ecotoxicol Environ Saf (1984) 1.08
Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol (2004) 1.07
Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine. J Chromatogr (1984) 1.07
Hepatic and extrahepatic scavenger receptors: function in relation to disease. Arterioscler Thromb Vasc Biol (2000) 1.06
Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation (2005) 1.06
Pharmacokinetics of temazepam compared with other benzodiazepine hypnotics--some clinical consequences. Acta Psychiatr Scand Suppl (1986) 1.06
Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine. Clin Pharmacol Ther (1977) 1.06
Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.05
The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J Psychopharmacol (1999) 1.05
Pharmacokinetics of methohexitone following intravenous infusion in humans. Br J Anaesth (1976) 1.05
In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim Biophys Acta (1994) 1.04
Endotoxin stimulates glycogenolysis in the liver by means of intercellular communication. J Biol Chem (1988) 1.04
Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat. J Pharmacol Exp Ther (1994) 1.04
Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach. Br J Clin Pharmacol (1988) 1.04
Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther (1989) 1.03
Processing of acetylated human low-density lipoprotein by parenchymal and non-parenchymal liver cells. Involvement of calmodulin? Biochem J (1982) 1.03
Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro. J Pharmacol Exp Ther (1996) 1.03
Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. Pharmacol Ther (1988) 1.02
Eicosanoid production by rat cerebral endothelial cells: stimulation by lipopolysaccharide, interleukin-1 and interleukin-6. J Neuroimmunol (1995) 1.01
Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thromb Res Suppl (1990) 1.01
Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol (2000) 1.01
Comparative pharmacokinetics of brotizolam and triazolam in healthy subjects. Br J Clin Pharmacol (1983) 1.01
In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur J Pharm Sci (2000) 1.01
Conditioned media of Kupffer and endothelial liver cells influence protein phosphorylation in parenchymal liver cells. Involvement of prostaglandins. Biochem J (1988) 1.00
Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier. Pharm Res (2000) 1.00